AHFS Drug Information (AHFS DI) is a leading source of evidence-based drug information.

AHFS DI is a dependable, comprehensive and objective database for FDA approved drug products. Inclusion of evidence-based data on labelled and unlabelled drug use makes this a valuable reference for healthcare professionals seeking to provide their patients with safe and effective therapy.

AHFS DI is published by the American Society of Health-System Pharmacists (ASHP).

SubscribeContent Updates
Features and Benefits icon

Comprehensive: Highly detailed monographs with extensive information on the chemistry and clinical application of all FDA approved drugs

Features and Benefits icon

Evidence-based: Built on evidence from primary sources and peer reviewed by over 500 pharmacists, physicians and healthcare professionals

Features and Benefits icon

Dependable: Fast and easy access to content that is revalidated, revised and updated regularly as new information arrives

Features and Benefits icon

Objective: The information is compiled without any influence from manufacturers, insurers, regulators or other interested parties

Publication Updates

12 Oct
AHFS Drug Information logo
AHFS October 2021 Update

This update contains 6 new monographs, 27 revised monographs, and 3 discontinued monographs.

New monographs: Odevixibat; Belumosudil; Fexinidazole; Anifrolumab; Avalglucosidase Alfa; Belzutifan

Revised monographs: Bendamustine; Tofacitinib; Trabectedin; Trifluridine and Tipiracil; Mepolizumab; Opicapone; Casirivimab and Imdevimab; COVID-19 Vaccine (Pfizer-BioNTech); COVID-19 Vaccine (Moderna); Bamlanivimab and Etesevimab; Fluorides; Dexamethasone; Hydrocortisone; methylPREDNISolone; predniSONE; Antituberculosis Agents General Statement; Corticosteroids General Statement; Erythromycins General Statement; Amoxicillin/Clavulanate; Aminopenicillins General Statement; Natural Penicillins General Statement; Penicillinase-Resistant Penicillins General Statement; Buprenorphine; Ritonavir; Antiretroviral Agents General Statement; Rifapentine; Efavirenz

Discontinued monographs: Capreomycin; Didanosine; Stavudine

14 Sep
AHFS Drug Information logo
AHFS September 2021 Update

This update contains 4 new monographs, 31 revised monographs, 2 discontinued monographs and 9 new MedWatch alerts.

New monographs: Ibrexafungerp; Bupivacaine and Meloxicam; Asparaginase (Erwinia chrysanthemi) (recombinant)-rywn; Finerenone

Revised monographs: Atorvastatin; HMG-CoA Reductase Inhibitors General Statement; Alemtuzumab; Fenofibrate; Colesevelam; Rosuvastatin; Pitavastatin; Alirocumab; Evolocumab; Cannabidiol; Isatuximab-irfc; Sacituzumab Govitecan-hziy; Tucatinib; Capmatinib; Ofatumumab; Casirivimab and Imdevimab; Oliceridine Fumarate; Fluorouracil; Colestipol; Melphalan; Bacitracin; Niacin; Cholestyramine; Opiate Agonists General Statement; Naltrexone; Gemfibrozil; Lovastatin; CloZAPine; Pravastatin; Simvastatin; Fluvastatin

Discontinued monographs: Betrixaban; Bacitracin

New MedWatch alerts on the following monographs: HMG-CoA Reductase Inhibitors General Statement; Atorvastatin; Rosuvastatin; Pitavastatin; Lovastatin; Pravastatin; Simvastatin; Fluvastatin; Melphalan

10 Aug
AHFS Drug Information logo
AHFS August 2021 Update

This update contains 6 new monographs, 33 revised monographs, 1 discontinued monograph and 1 new MedWatch alert.

New monographs: Sotorasib; Infigratinib; Relugolix, Estradiol, and Norethindrone Acetate; Aducanumab-avwa; Plasminogen, Human-tmvh; Pegcetacoplan

Revised monographs: Repaglinide; Nateglinide; Exenatide; SITagliptin; Miglitol; Liraglutide; SAXagliptin; Linagliptin; Alogliptin; Canagliflozin; Dapagliflozin Propanediol; Dulaglutide; Empagliflozin; Obeticholic Acid; Lixisenatide; Semaglutide; Ertugliflozin L-pyroglutamic Acid; COVID-19 Vaccine (Pfizer-BioNTech); COVID-19 Vaccine (Moderna); Bamlanivimab and Etesevimab; TOLBUTamide; GlyBURIDE; GlipiZIDE; BusPIRone; Rifabutin; MetFORMIN; Acarbose; Glimepiride; Meropenem; Pioglitazone; Rosiglitazone; EpiRUBicin; Exemestane

Discontinued monograph: Bamlanivimab

New MedWatch alerts on the following monograph: Obeticholic Acid

13 Jul
AHFS Drug Information logo
AHFS July 2021 Update

This update contains 5 new monographs and 16 revised monographs.

New monographs: Viloxazine; Dostarlimab; Loncastuximab Tesirine-lpyl; Amivantamab; Sotrovimab

Revised monographs: Entacapone; Ezetimibe; Fremanezumab-vfrm; Ubrogepant; Bempedoic Acid; Eptinezumab-jjmr; Tafasitamab-cxix; Belantamab Mafodotin-blmf; Casirivimab and Imdevimab; COVID-19 Vaccine (Pfizer-BioNTech); Relugolix; Bamlanivimab and Etesevimab; COVID-19 Vaccine (Janssen); MethazolAMIDE; AcetaZOLAMIDE; Tolcapone

08 Jun
AHFS Drug Information logo
AHFS June 2021 Update

This update contains 4 new monographs and 8 revised monographs.

New monographs: Tranexamic Acid; Fosdenopterin; Tivozanib; Dasiglucagon

Revised monographs: Propofol; Vedolizumab; Eteplirsen; Golodirsen; Pemigatinib; Remdesivir; Bamlanivimab; COVID-19 Vaccine (Janssen)

11 May
AHFS Drug Information logo
AHFS May 2021 Update

This update contains 12 new monographs and 38 revised monographs.

New monographs: Smallpox Vaccine Live; Fenfluramine; Smallpox and Monkeypox Vaccine Live; Ebola Zaire Vaccine Live; Bamlanivimab and Etesevimab; Tepotinib; Evinacumab-dgnb; Umbralisib; Trilaciclib; COVID-19 Vaccine (Janssen); Casimersen; Ponesimod

Revised monographs: Tapentadol; Bamlanivimab; Casirivimab and Imdevimab; Vibegron; COVID-19 Vaccine (Pfizer-BioNTech); COVID-19 Vaccine (Moderna); Relugolix; Naxitamab-gqgk; HYDROcodone; Tuberculin; HYDROmorphone; Levorphanol; Codeine; Electrolytes; Meperidine; Thioridazine; OxyMORphone; OxyCODONE; Morphine; Methadone; Naloxone; Mafenide; Opium; Pentazocine; Urea; Sodium Thiosulfate; Carbol-Fuchsin; FentaNYL; Irrigating Solutions; Butorphanol; Nalbuphine; Thyroid Agents General Statement; Cathartics and Laxatives General Statement; Metoclopramide; Naltrexone; Buprenorphine; Interferon Alfa; TraMADol

View more View all content updates